Abrocitinib | Interleukin Related interleukin-related.com

Product Name :
Abrocitinib

Search keywords :
Abrocitinib

drugId :
null

Target Vo:
Tyrosine-protein kinase JAK1

Target Vo Short Name :
JAK1

Moa_Name:
Tyrosine-protein kinase JAK1 inhibitors

First Approval Country :
United Kingdom

First Approval Date Filter:
2021

Origin Company_Name :
Pfizer Inc

Active Company_Name :
Glenmark Pharmaceuticals Ltd

Active Indication_Name:
Dermatitis, Atopic

In Active Indication_Name:
Hepatic Insufficiency

Termination Status :

China Termination Status :

Highest Status:
Approved

China Highest Status:
Approved

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Astegolimab MedChemExpress
Apitegromab MedChemExpress
PRMT1 Antibody (YA686): PRMT1 Antibody (YA686) is a non-conjugated and Mouse origined monoclonal antibody about 42 kDa, targeting to PRMT1 (4E9). It can be used for WB assays with tag free, in the background of Human.

Author: Interleukin Related

Related Posts